Clovis Oncology (NASDAQ:CLVS) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

A number of other equities analysts have also commented on the stock. Credit Suisse Group set a $86.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Clovis Oncology in a report on Thursday, January 11th. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Finally, Oppenheimer reiterated a “hold” rating on shares of Clovis Oncology in a report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. Clovis Oncology presently has a consensus rating of “Hold” and a consensus target price of $90.43.

Clovis Oncology (CLVS) opened at $50.12 on Friday. Clovis Oncology has a 1-year low of $45.42 and a 1-year high of $99.45. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. The company has a market cap of $2,460.00, a price-to-earnings ratio of -6.05 and a beta of 1.05.

In other news, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $64.97, for a total value of $292,365.00. Following the sale, the director now owns 21,118 shares in the company, valued at approximately $1,372,036.46. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total transaction of $191,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,000 shares of company stock worth $1,123,425. Company insiders own 12.50% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC raised its stake in Clovis Oncology by 13.5% during the third quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock worth $196,826,000 after acquiring an additional 284,300 shares during the period. State Street Corp raised its stake in Clovis Oncology by 4.3% during the second quarter. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company’s stock worth $181,966,000 after acquiring an additional 80,171 shares during the period. Jennison Associates LLC raised its stake in Clovis Oncology by 0.6% during the fourth quarter. Jennison Associates LLC now owns 603,672 shares of the biopharmaceutical company’s stock worth $41,050,000 after acquiring an additional 3,503 shares during the period. Macquarie Group Ltd. raised its stake in Clovis Oncology by 56.0% during the third quarter. Macquarie Group Ltd. now owns 526,880 shares of the biopharmaceutical company’s stock worth $43,415,000 after acquiring an additional 189,211 shares during the period. Finally, Westfield Capital Management Co. LP raised its stake in Clovis Oncology by 45.8% during the third quarter. Westfield Capital Management Co. LP now owns 459,470 shares of the biopharmaceutical company’s stock worth $37,860,000 after acquiring an additional 144,300 shares during the period.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/clovis-oncology-clvs-downgraded-by-bidaskclub/1853809.html.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.